NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 11 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
27.2% YoY உயர்வில் ₹130.51 கோடி நிகர லாபம்; Caplin Point ஸ்டாண்டலோன் Q2 வருவாய் 38.1% உயர்வு
Caplin Point Laboratories நிறுவனம் Q2 FY27 (செப்டம்பர் 30, 2026 இல் முடிந்த காலாண்டு) க்கான ஸ்டாண்டலோன் வருவாயை ₹241.88 கோடி என அறிவித்துள்ளது; இது ₹175.18 கோடியிலிருந்து 38.1% YoY உயர்வு. இந்தக் காலாண்டில் ஸ்டாண்டலோன் நிகர லாபம் ₹130.51 கோடியை எட்டியது; Q2 FY26 இல் இது ₹102.59 கோடியாக இருந்தது. இது 27.2% வளர்ச்சியைக் குறிக்கிறது. H1 FY27 க்கு ஸ்டாண்டலோன் வருவாய் 24.3% YoY உயர்ந்து ₹444.83 கோடியானது; நிகர லாபம் 33.1% YoY உயர்ந்து ₹250.89 கோடியானது. முக்கிய துணை நிறுவனங்கள் இந்தக் காலாண்டில் ₹721.65 கோடி வருவாயும் ₹101.12 கோடி PAT ஐயும் ஈட்டின.
உச்சம் நம்பிக்கை
என்ன மாறியதுCaplin Point நிறுவனம் Q2 மற்றும் H1 FY27 க்கான நிதி முடிவுகளை முதலீட்டாளர் விளக்கக் குறிப்புடன் (Investor Presentation) அறிவித்தது.
ஏன் இது முக்கியம்வருவாயும் லாபமும் இரண்டிலும் நிலையான வளர்ச்சி, ஸ்டாண்டலோன் ஃபார்முலேஷன்ஸ் மற்றும் துணை நிறுவனச் செயல்பாடுகள் இரண்டிலும் விரிவடைந்திருப்பதைக் காட்டுகிறது; அதோடு உயர் வருவாய் விகிதங்களையும் தக்கவைக்கிறது.
ஸ்டாண்டலோன் வருவாய் (Q2): ₹241.88 கோடிஸ்டாண்டலோன் PAT (Q2): ₹130.51 கோடிH1 ஸ்டாண்டலோன் வருவாய்: ₹444.83 கோடிH1 ஸ்டாண்டலோன் PAT: ₹250.89 கோடிதுணை நிறுவனங்களின் Q2 வருவாய்: ₹721.65 கோடி
📅 குறுகிய காலம்சந்தையில் வருவாயும் லாபமும் YoY அடிப்படையில் வலுவாக வளர்ந்திருப்பதால் இது சாதகமாகப் பார்க்கப்பட வாய்ப்புள்ளது.
📈 நீண்ட காலம்வலுவான செயல்பாட்டுப் பணப்புழக்கம் US இன்ஜெக்டபிள்ஸ் சந்தையில் தொடர் விரிவாக்கத்துக்கும் Latin America வில் புதிய உற்பத்தித் திறன் அமைப்புக்கும் (greenfield capacity) ஆதரவளிக்கிறது.
⚠ அபாய எச்சரிக்கைகள்
Latin American நாணய ஏற்ற இறக்கத்துக்கு வெளிப்பாடு
ஸ்டெரைல் இன்ஜெக்டபிள் ஆலைகள் முழுவதிலும் ஒழுங்குமுறை இணக்கம்
👀 கவனிக்க வேண்டியவை
முதலீட்டாளர்கள் முதலீட்டாளர் விளக்கக் குறிப்பில் (Investor Presentation) முழு ஒருங்கிணைந்த செயல்திறன் விவரங்களைப் பாருங்கள்; FY27 இல் இலக்கிட்ட US ANDA ஃப்ரண்ட்-எண்ட் வெளியீடுகள் மற்றும் Mexico ஆலை செயல்பாட்டுத் தொடக்கம் ஆகியவற்றின் முன்னேற்றத்தைக் கண்காணியுங்கள்.
Caplin Point Laboratories announced that its subsidiary, Caplin One Labs Limited (COL), has received confirmation of Good Manufacturing Practices (GMP) compliance from INVIMA (Colombia). The approval applies to its manufacturing unit in Kakkalur, Tiruvallur District, Tamil Nadu. The clearance covers oncology drug products across sterile lyophilized powder for injection (vials) and non-sterile tablets and hard capsules. Formal certification is expected in due course, expanding the company's regulatory access in Latin America.
உச்சம் நம்பிக்கை
என்ன மாறியதுCaplin One Labs' Kakkalur manufacturing facility has cleared INVIMA's GMP compliance audit for oncology products.
ஏன் இது முக்கியம்Colombia is a key Latin American pharmaceutical market; this approval unlocks commercial export opportunities for high-value injectable and oral oncology formulations.
Facility location: Kakkalur, Tiruvallur District, Tamil NaduTarget market regulator: INVIMA (Colombia)Caplin Point TTM Revenue: ₹2,287 கோடிCaplin Point TTM PAT: ₹678 கோடி
📅 குறுகிய காலம்Supports positive sentiment around the company's regulatory execution and subsidiary facility ramp-up.
📈 நீண்ட காலம்Enables oncology portfolio commercialization in Colombia and potentially other Latin American markets that leverage INVIMA regulatory compliance.
⚠ அபாய எச்சரிக்கைகள்
Timeline and regulatory approvals for individual product registrations/dossiers
Currency volatility across Latin American export markets
👀 கவனிக்க வேண்டியவை
Track product dossier filings, commercial export rollouts of oncology formulations to Colombia, and receipt of the formal certificate.
Caplin Steriles Receives US FDA Form 483 With 10 Observations at Gummidipoondi Site
The US FDA completed an unannounced inspection of Caplin Steriles' (subsidiary of Caplin Point) injectable and ophthalmic facility at Gummidipoondi between August 13 and August 21, 2026. The inspection concluded with the issuance of Form 483 with 10 observations. The company confirmed the observations are procedural in nature, do not involve data integrity issues, and contain no repeat citations. Caplin Steriles is preparing a comprehensive response within the stipulated regulatory timeline.
உச்சம் நம்பிக்கை
என்ன மாறியதுUS FDA concluded an unannounced audit at Caplin Steriles' Gummidipoondi facility, issuing 10 Form 483 observations.
ஏன் இது முக்கியம்The Gummidipoondi sterile facility produces injectables and ophthalmics critical to Caplin's US front-end expansion; regulatory clearance is required to avoid product approval or supply delays.
Form 483 observations: 10Inspection start date: ஆகஸ்ட் 13, 2026Inspection end date: ஆகஸ்ட் 21, 2026TTM Revenue context: Rs 2287 கோடி
📅 குறுகிய காலம்Market may view 10 observations with caution until the formal response is accepted and an Establishment Inspection Report (EIR) is issued.
📈 நீண்ட காலம்If resolved smoothly without escalation to a Warning Letter or Official Action Indicated (OAI) status, Caplin's US injectable pipeline expansion remains intact.
⚠ அபாய எச்சரிக்கைகள்
Potential regulatory escalation (Warning Letter/OAI) if US FDA deems corrective responses inadequate
Possible delays in pending US ANDA approvals from the Gummidipoondi sterile facility
👀 கவனிக்க வேண்டியவை
Track the submission of the response within the 15-day regulatory window and subsequent classification by the US FDA (e.g., VAI or OAI status / EIR issuance).
19.6% Revenue Growth in Q1 FY27; Rs 4 Final Dividend Recommended
Caplin Point Laboratories reported a strong start to FY27 with consolidated revenue growing 19.6% YoY to ₹610.36 cr. Consolidated Net Profit increased by 18.8% YoY to ₹179.09 cr, reflecting stable operational efficiency. The Board recommended a final dividend of ₹4 per share (200%), bringing the total dividend for FY26 to ₹8 per share. Additionally, the company ensured leadership continuity by re-appointing Dr. Sridhar Ganesan as Managing Director for two years.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results, showing sustained double-digit growth, and confirmed a final dividend payment and management re-appointments.
ஏன் இது முக்கியம்The results validate the company's growth strategy in the US and LATAM markets, while the dividend and management continuity provide stability for shareholders.
Consolidated Revenue (Q1 FY27): ₹610.36 கோடிConsolidated PAT (Q1 FY27): ₹179.09 கோடிRevenue Growth (YoY): 19.6%Final Dividend: ₹4.00 per shareTotal FY26 Dividend: ₹8.00 per share
📅 குறுகிய காலம்The stock may see positive sentiment in the coming days due to the earnings beat and the dividend announcement.
📈 நீண்ட காலம்The company's focus on own-label expansion in the US and greenfield expansion in Mexico (FY27) supports a structural growth outlook.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical risks in LATAM/Africa markets
Potential US tariff measures impacting export costs
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the Mexico facility (Triwin Pharma) targeted for FY27 and the progress of the 15+ US product launches planned for the current fiscal year.
Caplin Point Re-appoints Dr. Sridhar Ganesan as MD; CFO D. Muralidharan Elevated to WTD
Caplin Point Laboratories has approved the re-appointment of Dr. Sridhar Ganesan as Managing Director for a two-year term effective August 25, 2026. Additionally, the current Chief Financial Officer, Mr. D. Muralidharan, has been elevated to the Board as a Whole-Time Director for a two-year term while continuing his role as CFO. These appointments ensure leadership continuity as the company pursues its FY26-27 expansion plans in the US, Mexico, and China. The company maintains a strong financial profile with a TTM PAT of Rs 650 Cr and an operating margin of 34.8%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the continuation of its Managing Director and elevated its long-standing CFO to a Board-level executive position.
ஏன் இது முக்கியம்Leadership stability is critical as Caplin Point transitions from a lean manufacturing model to more capital-intensive greenfield expansions in Mexico and front-end growth in the US market.
MD Re-appointment Term: 2 yearsWTD Appointment Term: 2 yearsCFO Tenure: Since Feb 2016TTM வருவாய்: Rs 2187 கோடிOperating Profit Margin: 34.8%
📅 குறுகிய காலம்The announcement is procedural and expected to have a neutral impact on the stock price in the immediate term.
📈 நீண்ட காலம்Ensures continuity in strategic execution, particularly for the 'Second Innings' in China and the US front-end expansion which are key long-term growth drivers.
👀 கவனிக்க வேண்டியவை
Investors should look for formal shareholder approval in the upcoming AGM and monitor if this leadership stability aids the timely commissioning of the Mexico facility targeted for FY27.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Caplin Point Q1 PAT Rises 16% YoY to ₹177 Cr; Recommends ₹4 Final Dividend
Caplin Point Laboratories reported a steady Q1 FY27 with consolidated revenue growing 19.6% YoY to ₹610.36 cr. Net profit attributable to owners increased 15.8% YoY to ₹176.91 cr, maintaining strong profitability with a PBT margin of approximately 36.9%. The board recommended a final dividend of ₹4 per share, bringing the total dividend for FY26 to ₹8 (400% of face value). Key leadership remains stable with the re-appointment of Dr. Sridhar Ganesan as MD and the elevation of CFO Mr. D. Muralidharan to Whole-Time Director.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its first-quarter results for FY27, showing consistent double-digit growth, and finalized its dividend recommendation for the previous fiscal year.
ஏன் இது முக்கியம்The results confirm the company's ability to scale its US and Latin American operations while maintaining high margins (OPM ~34.8% TTM) and a debt-free balance sheet.
Q1 Consolidated Revenue: ₹610.36 கோடிQ1 Net Profit (Owners): ₹176.91 கோடிYoY Revenue Growth: 19.6%Final Dividend per share: ₹4Q1 வருவாய் vs TTM வருவாய்: 27.9%
📅 குறுகிய காலம்The stock is likely to react positively to the steady earnings growth and the final dividend announcement in the coming weeks.
📈 நீண்ட காலம்The long-term outlook depends on the successful commissioning of the Mexico facility in FY27 and the 'Second Innings' strategy in China focusing on Peptides and Biosimilars.
⚠ அபாய எச்சரிக்கைகள்
Currency fluctuations in Latin American markets
Potential US tariff measures impacting export costs
Geopolitical risks in African and LATAM distribution networks
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline of the Mexico facility (Triwin Pharma) targeted for FY27 and the planned launch of 15+ new products in the US market during the remainder of FY26.
Caplin Point Promoters Declare Zero Share Encumbrance for FY 2025-26
The promoters and promoter group of Caplin Point Laboratories Limited have filed a formal declaration under SEBI (SAST) Regulations stating that no shares were encumbered during the financial year ended March 31, 2026. This disclosure confirms that the promoter holdings remain free from any direct or indirect pledges or liens. The declaration covers key promoter entities including Mr. C C Paarthipan and several private limited companies within the group. Such filings are essential for assessing the financial stability and leverage of the company's controlling shareholders.
முக்கிய அம்சங்கள்
Compliance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.Confirmation of zero encumbrances on promoter shares for the entire financial year ended March 31, 2026.Declaration covers 7 distinct entities/persons including the Promoter and Promoter Group.The filing was submitted to both BSE and NSE on April 06, 2026, ensuring transparency for public shareholders.
👀 கவனிக்க வேண்டியவை
Investors should take this as a sign of financial strength and high promoter confidence, as zero pledging reduces the risk of forced sell-offs. No immediate action is required, but it supports a positive long-term view on the stock's governance.
Caplin Steriles Gets USFDA Approval for Foscarnet Sodium Injection ($15M US Market)
Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Foscarnet Sodium Injection, a generic version of Foscavir. The medication is used to treat CMV retinitis and HSV infections in immunocompromised patients. The product addresses a US market size of approximately $15 million based on IQVIA data for the 12 months ending March 2026. This approval marks the 55th USFDA approval for the subsidiary, which continues to build a robust pipeline of over 55 injectable and ophthalmic products.
முக்கிய அம்சங்கள்
Final USFDA approval received for Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag).Target US market sales for this product were approximately $15 million for the year ending March 2026.Caplin Steriles now holds a total of 55 USFDA approvals including acquired ANDAs.The company is developing a portfolio of 55+ simple and complex injectable products for filing over the next 4 years.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook as the company continues to successfully navigate the US regulatory landscape and expand its injectable portfolio. Monitor the commercialization timeline and market share capture in the US generic space.
Caplin Point Declares INR 4 Dividend; FY26 Consolidated Net Profit Reaches INR 302.97 Cr
Caplin Point Laboratories has declared an interim dividend of INR 4.00 per share (200% of face value) for FY26, with the record date set for May 30, 2026. The company reported a strong financial performance for the year ended March 31, 2026, with consolidated revenues reaching INR 2,038.02 Crores. Annual net profit after tax stood at INR 302.97 Crores, while the fourth quarter alone contributed INR 86.96 Crores to the bottom line. The statutory auditors have issued an unmodified opinion, confirming the reliability of the financial statements.
முக்கிய அம்சங்கள்
Interim dividend of INR 4.00 per equity share (200% on face value of INR 2)Record date for dividend eligibility fixed as May 30, 2026FY26 Consolidated Revenue of INR 2,038.02 Crores and Net Profit of INR 302.97 CroresQ4 FY26 performance recorded revenue of INR 605.12 Crores and Net Profit of INR 86.96 CroresStatutory auditors issued an unmodified audit opinion for both standalone and consolidated results
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold the stock prior to the ex-dividend date to qualify for the INR 4.00 payout. The robust annual profit growth and clean audit report support a positive long-term outlook for the company.
Caplin Point Laboratories reported a strong financial performance for FY26, with consolidated annual revenue reaching ₹2,038.02 crore. The company's annual net profit after tax stood at ₹302.97 crore, supported by a healthy Q4 PAT of ₹86.96 crore. In addition to the earnings, the board declared an interim dividend of ₹4.00 per share (200% of face value) for the financial year. The company maintains a robust balance sheet with total assets valued at ₹3,463.44 crore as of March 31, 2026.
முக்கிய அம்சங்கள்
Consolidated annual revenue for FY26 reached ₹2,038.02 croreAnnual Net Profit After Tax (PAT) reported at ₹302.97 croreDeclared an interim dividend of ₹4.00 per equity share (200% on face value of ₹2)Q4 FY26 consolidated revenue and PAT stood at ₹605.12 crore and ₹86.96 crore respectivelyStatutory auditors issued an unmodified opinion on the financial statements
👀 கவனிக்க வேண்டியவை
Investors should consider the consistent revenue growth and the 200% dividend payout as positive indicators of financial health. Ensure holdings are maintained before the May 30, 2026 record date to qualify for the interim dividend.
Caplin Point Subsidiary Gets USFDA Approval for Calcium Gluconate Injection; $71M Market Size
Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Calcium Gluconate Injection USP, a generic equivalent of Fresenius Kabi's RLD. The product is used for treating acute symptomatic hypocalcemia in pediatric and adult patients. According to IQVIA data, the US market for this injection was approximately $71 million for the 12-month period ending March 2026. This approval adds to the company's growing portfolio of 54 approved ANDAs, marking a significant step in their US sterile injectables expansion.
முக்கிய அம்சங்கள்
Final USFDA approval received for Calcium Gluconate Injection USP in 10 mL, 50 mL, and 100 mL vials.Addressable US market size estimated at $71 million for the 12 months ending March 2026.Caplin Steriles now holds 54 ANDA approvals in the USA, including acquired ANDAs.The company has a robust pipeline of 55+ simple and complex injectable and ophthalmic products for future filing.The product targets acute symptomatic hypocalcemia in both adult and pediatric patient segments.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth catalyst for the company's US sterile injectables business. Monitor the company's ability to gain market share in this $71 million segment and the progress of its 55+ product pipeline.
Caplin Point Subsidiary Gets USFDA Approval for Potassium Phosphates Injection ($57M Market)
Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Potassium Phosphates Injection USP, a generic version of Fresenius Kabi's reference drug. The product is used to treat hypophosphatemia and as parenteral nutrition for patients who cannot take oral supplements. According to IQVIA data, the addressable US market for this product was approximately $57 million for the 12-month period ending January 2026. This approval marks the 53rd for the subsidiary, which maintains a high success rate with 53 approvals out of 54 ANDAs filed.
முக்கிய அம்சங்கள்
Final USFDA approval received for Potassium Phosphates Injection USP in 5 mL, 15 mL, and 50 mL vials.Addressable US market size for the product is approximately $57 million as of January 2026.Caplin Steriles has now secured 53 approvals out of 54 ANDAs filed in the US market.The company is currently working on a pipeline of 55+ simple and complex injectable and ophthalmic products.Product serves a critical medical need for parenteral nutrition in both adult and pediatric patients.
👀 கவனிக்க வேண்டியவை
This approval strengthens Caplin Point's US portfolio and provides a clear revenue growth path in the sterile injectables segment. Investors should monitor the company's execution in capturing market share within this $57 million segment and the progress of its extensive 55+ product pipeline.
Caplin Point Subsidiary Gets USFDA Approval for Desmopressin Acetate Injection
Caplin Point's subsidiary, Caplin Steriles, has received final USFDA approval for Desmopressin Acetate Injection USP, a generic version of Nordic Pharma's DDAVP. The injection is used to treat haemophilia A and diabetes insipidus, targeting a US market valued at approximately $26 million as of December 2025. This approval brings the subsidiary's total USFDA approvals to 52 out of 54 ANDAs filed, showcasing a robust regulatory track record. The company maintains a strong pipeline with over 55 products planned for filing in the next four years.
முக்கிய அம்சங்கள்
Final USFDA approval received for Desmopressin Acetate Injection USP in single and multi-dose vials.Target US market size for the product is approximately $26 million for the 12-month period ending December 2025.Caplin Steriles has now achieved 52 approvals out of 54 ANDAs filed in the US market.Company pipeline includes 55+ simple and complex injectable and ophthalmic products for the next 4 years.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial rollout of this product as it adds to the company's growing US injectable portfolio. The high approval-to-filing ratio reflects strong execution capabilities in the regulated US market.
Caplin Point Subsidiary Receives USFDA Approval for Sodium Phosphates Injection ($67M Market)
Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for Sodium Phosphates Injection USP, a generic equivalent of Hospira's reference drug. The product is used to treat hypophosphatemia and addresses a US market estimated at approximately $67 million for the 12-month period ending December 2025. This approval brings the subsidiary's total USFDA approvals to 51 out of 54 ANDAs filed, highlighting a strong regulatory track record. The company is actively developing a pipeline of over 55 additional injectable and ophthalmic products for future filings.
முக்கிய அம்சங்கள்
Final USFDA approval received for Sodium Phosphates Injection USP in three vial sizes (5mL, 15mL, and 50mL).Target US market size for this product is approximately $67 million as of December 2025 per IQVIA data.Caplin Steriles has achieved 51 approvals out of 54 ANDAs filed to date in the US market.The company has a robust pipeline of 55+ simple and complex injectable and ophthalmic products planned for the next 4 years.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive expansion of Caplin's US sterile injectable portfolio, which is a high-margin segment. Monitor the company's ability to convert these approvals into market share and revenue growth in the upcoming quarters.
Caplin Point Q3 Standalone Net Profit Grows 16.8% YoY to ₹87.28 Cr; Revenue Up 2.1%
Caplin Point Laboratories reported a standalone net profit of ₹87.28 crore for the quarter ended December 31, 2025, marking a 16.8% increase over the ₹74.71 crore reported in the same period last year. Revenue from operations saw a modest growth of 2.1% YoY, reaching ₹189.22 crore. For the nine-month period (9M FY26), standalone net profit rose to ₹275.79 crore from ₹252.99 crore in 9M FY25. The company maintained strong profitability despite a slight sequential dip in revenue and profit compared to Q2 FY26.
முக்கிய அம்சங்கள்
Standalone Net Profit increased 16.8% YoY to ₹87.28 crore in Q3 FY26.Revenue from operations grew slightly to ₹189.22 crore from ₹185.23 crore in Q3 FY25.9M FY26 Standalone Net Profit reached ₹275.79 crore, showing steady growth from ₹252.99 crore YoY.Total expenses for the quarter were reduced to ₹103.94 crore from ₹113.89 crore in the previous year's quarter.A minor impact of ₹0.84 crore was recognized due to the implementation of new Labour Codes.
👀 கவனிக்க வேண்டியவை
The company shows strong bottom-line growth on a standalone basis, driven by effective cost control. Investors should hold for long-term growth but wait for the full consolidated presentation to assess the performance of international subsidiaries.
Caplin Point Appoints Two Vice-Chairmen and Retired IAS Officer to Board
Caplin Point Laboratories has received shareholder approval for the appointment of four directors following a postal ballot on January 31, 2026. Mr. Ashok Partheeban and Mr. Vivek Partheeban have been appointed as Vice-Chairmen of the company. Additionally, the board has been strengthened with the appointment of Mrs. Susan Mathew, a retired IAS officer with 36 years of administrative experience, and Dr. K C John as Independent Directors for five-year terms. These appointments are aimed at enhancing corporate governance and strategic oversight.
முக்கிய அம்சங்கள்
Ashok Partheeban and Vivek Partheeban appointed as Vice-Chairmen effective November 5, 2025Mrs. Susan Mathew, a 1975 batch retired IAS officer, appointed as Independent Director for 5 yearsDr. K C John appointed as Independent Director for a 5-year term starting November 5, 2025Mrs. Susan Mathew brings over 36 years of experience, having served as Additional Chief Secretary and CMD of TIDCOAll appointments were approved by shareholders via Postal Ballot concluded on January 31, 2026
👀 கவனிக்க வேண்டியவை
Investors should view the addition of a highly experienced former bureaucrat and the formalization of leadership roles as a positive step for corporate governance. No immediate portfolio changes are necessary based on this administrative update.
Caplin Point Shareholders Approve Key Leadership and Independent Director Appointments
Caplin Point Laboratories has successfully passed four key resolutions through a postal ballot as of February 3, 2026. Shareholders approved the appointments of Mr. Ashok Partheeban and Mr. Vivek Partheeban as Directors and Vice-Chairmen of the company. Furthermore, the board has been strengthened with the appointment of Dr. K C John and Mrs. Susan Mathew as Non-Executive Independent Directors for five-year terms. All resolutions were passed with the requisite majority, ensuring leadership continuity and enhanced corporate governance.
முக்கிய அம்சங்கள்
Appointment of Mr. Ashok Partheeban as Director and Vice-Chairman approved by shareholdersAppointment of Mr. Vivek Partheeban as Director and Vice-Chairman approved by shareholdersDr. K C John appointed as Non-Executive Independent Director for a fixed term of 5 yearsMrs. Susan Mathew appointed as Non-Executive Independent Director for a fixed term of 5 yearsAll resolutions passed with requisite majority via remote e-voting results declared on Feb 3, 2026
👀 கவனிக்க வேண்டியவை
Investors should take note of the leadership continuity and the addition of independent oversight to the board. No immediate action is required as these appointments align with standard corporate governance practices.
Caplin Point Subsidiary Gets USFDA Approval for Generic Depo-Medrol; $57.4M Market Opportunity
Caplin Point's subsidiary, Caplin Steriles, has secured final USFDA approval for Methylprednisolone Acetate Injectable Suspension, a generic version of Pfizer's Depo-Medrol. The product addresses a US market valued at approximately $57.4 million for the 12 months ending November 2025. This approval brings the subsidiary's total USFDA approvals to 50 out of 53 filings. The company continues to build a strong pipeline with over 55 injectable and ophthalmic products currently under development for the next four years.
முக்கிய அம்சங்கள்
Final USFDA approval received for Methylprednisolone Acetate Injectable (40mg/mL & 80mg/mL).Addresses a US market opportunity of approximately $57.4 million annually as per IQVIA data.Milestone 50th approval for subsidiary Caplin Steriles Limited out of 53 ANDA filings.Strong future pipeline with 55+ simple and complex injectable products in development.
👀 கவனிக்க வேண்டியவை
This approval reinforces Caplin Point's execution capabilities in the high-margin sterile injectables space. Investors should monitor the commercial launch and subsequent market share capture in the US.
Caplin Point Acquires 10 Approved ANDAs with $473.2 Million Addressable Market
Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) from a leading multinational generic company. The acquired portfolio focuses on Injectable and Ophthalmic products, which had an addressable market of $473.2 million for the 12-month period ending August 2025. This acquisition includes oncology injectables that will be manufactured at the company's new dedicated facility in Kakkalur. The company plans to commercialize these products in the U.S. and progressively expand into Mexico, Canada, the EU, and Brazil.
முக்கிய அம்சங்கள்
Acquisition of 10 approved ANDAs for Injectable and Ophthalmic products from a major MNCAddressable market for the acquired products valued at $473.2 million as of August 2025Caplin Steriles now has 49 approvals out of 53 ANDA filings in the USAIncludes oncology injectables to be commercialized from the new dedicated Kakkalur facilityStrategic expansion planned for regulated markets including Canada, EU, and Brazil
👀 கவனிக்க வேண்டியவை
This acquisition is a significant positive as it provides immediate access to approved products in high-value segments, bypassing long R&D and approval cycles. Investors should monitor the commercialization timeline and the resulting revenue growth in the U.S. and other regulated markets.
Caplin Point Seeks Approval for Appointment of Vice-Chairmen and Independent Directors
Caplin Point Laboratories has initiated a postal ballot to obtain shareholder approval for several key board appointments. The company proposes appointing Mr. Ashok Partheeban and Mr. Vivek Partheeban as Directors and Vice-Chairmen to provide strategic guidance. Furthermore, Dr. K C John and Mrs. Susan Mathew are nominated as Independent Directors for five-year tenures, despite both reaching the age of 75 during their terms. The e-voting window for these resolutions is open from January 2, 2026, until January 31, 2026.
முக்கிய அம்சங்கள்
Appointment of two new Vice-Chairmen, Mr. Ashok Partheeban and Mr. Vivek Partheeban, effective Nov 5, 2025Nomination of Dr. K C John as Independent Director for a 5-year term starting November 2025Nomination of Mrs. Susan Mathew as Independent Director for a 5-year term starting January 2026E-voting period scheduled for 30 days from Jan 2 to Jan 31, 2026, for all eligible shareholders
👀 கவனிக்க வேண்டியவை
Monitor the transition in leadership as the new Vice-Chairmen take on strategic roles. Shareholders should exercise their voting rights during the January 2026 window.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
